Your browser doesn't support javascript.
loading
Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.
Lo Monaco, Maria Rita; Petracca, Martina; Vetrano, Davide Liborio; Di Stasio, Enrico; Fusco, Domenico; Ricciardi, Diego; Laudisio, Alice; Zuccalà, Giuseppe; Onder, Graziano; Bentivoglio, Anna Rita.
  • Lo Monaco MR; Institute of Internal Medicine and Geriatrics, Università Cattolica del Sacro Cuore, 00168, Rome, Italy. rita.lomonaco@gmail.com.
  • Petracca M; Fondazione Policlinico Universitario "Agostino Gemelli"-IRCSS, Largo A Gemelli, 8, 00168, Rome, Italy. rita.lomonaco@gmail.com.
  • Vetrano DL; Fondazione Policlinico Universitario "Agostino Gemelli"-IRCSS, Largo A Gemelli, 8, 00168, Rome, Italy.
  • Di Stasio E; Institute of Neurology, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
  • Fusco D; Institute of Internal Medicine and Geriatrics, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
  • Ricciardi D; Aging Research Centre, Karolinska Institutet, Stockholm, Sweden.
  • Laudisio A; Fondazione Policlinico Universitario "Agostino Gemelli"-IRCSS, Largo A Gemelli, 8, 00168, Rome, Italy.
  • Zuccalà G; Institute of Biochemistry and Clinical Biochemistry, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
  • Onder G; Institute of Internal Medicine and Geriatrics, Università Cattolica del Sacro Cuore, 00168, Rome, Italy.
  • Bentivoglio AR; Fondazione Policlinico Universitario "Agostino Gemelli"-IRCSS, Largo A Gemelli, 8, 00168, Rome, Italy.
Aging Clin Exp Res ; 32(7): 1369-1373, 2020 Jul.
Article en En | MEDLINE | ID: mdl-31981101
ABSTRACT

BACKGROUND:

Safinamide, as a levodopa adjunct, is effective in reducing motor fluctuations in Parkinson's disease (PD) patients; however, scarce evidence is available regarding its use in older PD patients.

AIM:

To evaluate the safety and tolerability of safinamide as an adjunct therapy in patients aged ≥ 60 years with advanced PD.

METHODS:

A retrospective study including 203 PD patients admitted to a geriatric day hospital, who were evaluated following an extensive clinical protocol. Safinamide use was categorized as never used, ongoing, and withdrawn. Potential correlations of Safinamide withdrawal were investigated in stepwise backward logistic regression models.

RESULTS:

A total of 44 out of 203 participants were current or former users of Safinamide. Overall, 14 (32%) patients discontinued due to treatment-emergent adverse events (TEAEs). Withdrawal was not associated with older age.

CONCLUSIONS:

Safinamide as an adjunct therapy in patients aged ≥ 60 years with advanced PD was found to be safe and well-tolerated in older patients. There were no specific demographic or clinical characteristics associated with suspension.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Bencilaminas / Alanina / Antiparkinsonianos Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Middle aged Idioma: En Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Bencilaminas / Alanina / Antiparkinsonianos Tipo de estudio: Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans / Middle aged Idioma: En Año: 2020 Tipo del documento: Article